The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument

被引:43
作者
Lebwohl, Mark [1 ]
Swensen, Andrine R. [1 ]
Nyirady, Judit [1 ]
Kim, Edward [1 ]
Gwaltney, Chad J. [1 ]
Strober, Bruce E. [1 ]
机构
[1] Novartis Pharmaceut, PRO Consulting, Westerly, RI USA
关键词
QUALITY-OF-LIFE; PRO INSTRUMENTS; SEVERITY INDEX; IMPACT; DISABILITY; AREA; PAIN;
D O I
10.1111/j.1365-4632.2012.05798.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100227 [皮肤病学];
摘要
BackgroundChronic plaque psoriasis has a profound impact on a patient's daily life. To understand the effects of psoriasis treatments, it is essential to assess the patient's experience of symptoms and how they impact their daily life. The goal of this study was to develop and establish the content validity of a new patient reported outcome (PRO) psoriasis measure. MethodsThe Psoriasis Symptom Diary was developed by (i) identifying key plaque psoriasis-related symptoms and impacts through qualitative patient interviews (n=29); (ii) developing an initial set of items that captured the key patient experiences; and (iii) conducting cognitive interviews to test patient understanding of items selected for inclusion in the new psoriasis symptom measure (n=16). ResultsPatients noted a variety of symptoms, with plaque-related pain (including related concepts of burning and stinging), changes in skin appearance, and itching reported by all patients. Patients also expressed notable embarrassment and avoidance of social situations, due to the appearance of plaques, and limited mobility. The Psoriasis Symptom Diary assesses the severity and impact of symptoms using a 24-hour recall period to reduce recall bias and error. ConclusionsThe Psoriasis Symptom Diary was developed to assess important symptoms and disease-related impacts in a manner consistent with guidelines for establishing the content validity of new PRO instruments. Following quantitative psychometric testing, the Psoriasis Symptom Diary may support efficacy endpoints in clinical trials.
引用
收藏
页码:714 / 722
页数:9
相关论文
共 19 条
[1]
[Anonymous], 2009, GUID IND PAT REP OUT
[2]
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis [J].
Carlin, CS ;
Feldman, SR ;
Krueger, JG ;
Menter, A ;
Krueger, GG .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (06) :859-866
[3]
Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases [J].
Chren, MM ;
Lasek, RJ ;
Flocke, SA ;
Zyzanski, SJ .
ARCHIVES OF DERMATOLOGY, 1997, 133 (11) :1433-1440
[4]
European patient perspectives on the impact of psoriasis:: the EUROPSO patient membership survey [J].
Dubertret, L. ;
Mrowietz, U. ;
Ranki, A. ;
van de Kerkhof, P. C. M. ;
Chimenti, S. ;
Lotti, T. ;
Schaefer, G. .
BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (04) :729-736
[5]
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations [J].
Dworkin, RH ;
Turk, DC ;
Farrar, JT ;
Haythornthwaite, JA ;
Jensen, MP ;
Katz, NP ;
Kerns, RD ;
Stucki, G ;
Allen, RR ;
Bellamy, N ;
Carr, DB ;
Chandler, J ;
Cowan, P ;
Dionne, R ;
Galer, BS ;
Hertz, S ;
Jadad, AR ;
Kramer, LD ;
Manning, DC ;
Martin, S ;
McCormick, CG ;
McDermott, MP ;
McGrath, P ;
Quessy, S ;
Rappaport, BA ;
Robbins, W ;
Robinson, JP ;
Rothman, M ;
Royal, MA ;
Simon, L ;
Stauffer, JW ;
Stein, W ;
Tollett, J ;
Wernicke, J ;
Witter, J .
PAIN, 2005, 113 (1-2) :9-19
[6]
What criteria do patients use when judging the effectiveness of psoriasis management? [J].
Ersser, SJ ;
Surridge, H ;
Wiles, A .
JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2002, 8 (04) :367-376
[7]
Decision points for the initiation of systemic treatment for psoriasis [J].
Feldman, SR ;
Koo, JYM ;
Menter, A ;
Bagel, J .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 53 (01) :101-107
[8]
DERMATOLOGY LIFE QUALITY INDEX (DLQI) - A SIMPLE PRACTICAL MEASURE FOR ROUTINE CLINICAL USE [J].
FINLAY, AY ;
KHAN, GK .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (03) :210-216
[9]
FINLAY AY, 1995, BRIT J DERMATOL, V132, P236
[10]
Why are quality of life instruments not recognized as reference measures in therapeutic trials of chronic skin disorders? [J].
Grob, Jean Jacques .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (10) :2299-2301